C 19 H 27 NO 3 , monoclinic, P21/c (no. 14), a = 6.6207 ( 
T = 296(2) K.
CCDC no.: 1500471
The asymmetric unit of the title crystal structure is shown in the gure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
The title compound was prepared by a literature method [1] . In a 250 mL three-neck ask equipped with a mechanical stirrer, a mixture of acetyltropyl chloride (8.66 g, 34 mmol) and Nisopropylnortropine (3.4 g, 32 mmol) was heated at 85 degree for 6 h. The mixture was cooled and dissolved in chloroform (150 mL). The chloroform solution was poured into an aqueous solution of 5% hydrochloric acid (500 mL). The two-phase . 
( ) . * mixture was stirred vigorously for 24 h. The aqueous phase was extracted with 50 mL of chloroform for 3 times, and the chloroform extracts were discarded. The aqueous phase was adjusted to pH 10 with a saturated sodium carbonate solution and extracted with 300 mL of chloroform. The combined chloroform extracts were washed with water, followed by a saturated sodium chloride solution, and dried with sodium sulfate. Removal of solvent under reduced pressure left a yellow colored liquid (5.5 g, 60% crude yield). Crystallization from acetone by slow evaporation at room temperature for about 15 d gave prism-shaped crystals of the title compound.
Experimental details
All hydrogen atoms were identi ed in di erence Fourier syntheses. The hydrogen atoms were placed on calculated positions with the help of the SHELX program [5] . Due to the experimental conditions of crystal mounting an absorption correction was applied.
Discussion
The title compound, another drug name is N-isopropylnoratropine, is a Noratropine derivative and an important intermediate in the production of Ipratropium [2] . Ipratropium bromide was developed in Germany in 1976. It was approved for medical use in the USA in 1986. It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system. Ipratropium is available as a generic medication. Ipratropium bromide, sold under the trade name Atrovent among others, is a medication that opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease and asthma. It is used by inhaler or nebulizer. The compound reported here, N-isopropylnoratropine is the most important intermediate. It plays a key role in the production of ipratropium bromide. The molecular structure of the title compound is shown in the gure. The bond lengths and angles are within normal ranges. In the crystal structure of the title compound the rings, A(N1-C1-C2-C3-C4), B(N1-C1-C7-C6-C5-C4), and C(C1-C2-C3-C4-C5-C6-C7), are not planar. In the molecular structure of the title compound, there are three chiral carbon atoms C1, C4 and C12; but the compound is obtained as a racemic mixture (S,R,S and R,S,R). In the crystal of the title compound, there are weak C-H· · · O hydrogen bonds which seems to be e ective in stabilization the crystal structure. The strongest hydrogen bonds are intermolecular O-H· · · N connections which link the molecules to chains along [010] .
